Investment analysts at StockNews.com assumed coverage on shares of LifeVantage (NASDAQ:LFVN – Get Rating) in a research report issued on Wednesday. The brokerage set a “strong-buy” rating on the stock.
LifeVantage Price Performance
Shares of LFVN opened at $3.83 on Wednesday. The stock’s 50-day moving average is $3.80 and its two-hundred day moving average is $3.89. The stock has a market cap of $48.14 million, a PE ratio of 95.75 and a beta of 1.10. LifeVantage has a 12 month low of $3.46 and a 12 month high of $6.68.
LifeVantage (NASDAQ:LFVN – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The company reported $0.06 EPS for the quarter. The company had revenue of $51.77 million for the quarter. LifeVantage had a return on equity of 9.48% and a net margin of 0.20%. On average, research analysts anticipate that LifeVantage will post 0.33 earnings per share for the current year.
Institutional Inflows and Outflows
LifeVantage Company Profile
LifeVantage Corp. engages in the identification, research, development and distribution of advanced nutraceutical dietary supplements and personal care products. The firm operates through the following geographical segments: Americas Region, and Asia/Pacific and Europe Region. Its products include Protandim, LifeVantage Omega+ and ProBio, TrueScience and Petandim for dogs.
- Get a free copy of the StockNews.com research report on LifeVantage (LFVN)
- Is It Time To Get Aggressive With Defense Stocks?
- 3 Retail Stocks Ringing the Register in 2023
- When Will Crane Holdings Take Flight?
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.